1. Home
  2. CTMX vs VNRX Comparison

CTMX vs VNRX Comparison

Compare CTMX & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • VNRX
  • Stock Information
  • Founded
  • CTMX 2008
  • VNRX N/A
  • Country
  • CTMX United States
  • VNRX United States
  • Employees
  • CTMX N/A
  • VNRX N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • CTMX Health Care
  • VNRX Health Care
  • Exchange
  • CTMX Nasdaq
  • VNRX Nasdaq
  • Market Cap
  • CTMX 444.3M
  • VNRX 52.4M
  • IPO Year
  • CTMX 2015
  • VNRX N/A
  • Fundamental
  • Price
  • CTMX $2.42
  • VNRX $0.66
  • Analyst Decision
  • CTMX Strong Buy
  • VNRX Strong Buy
  • Analyst Count
  • CTMX 2
  • VNRX 5
  • Target Price
  • CTMX $5.00
  • VNRX $3.88
  • AVG Volume (30 Days)
  • CTMX 2.4M
  • VNRX 319.2K
  • Earning Date
  • CTMX 08-07-2025
  • VNRX 08-13-2025
  • Dividend Yield
  • CTMX N/A
  • VNRX N/A
  • EPS Growth
  • CTMX 128.27
  • VNRX N/A
  • EPS
  • CTMX 0.49
  • VNRX N/A
  • Revenue
  • CTMX $147,557,000.00
  • VNRX $1,308,361.00
  • Revenue This Year
  • CTMX N/A
  • VNRX $563.72
  • Revenue Next Year
  • CTMX N/A
  • VNRX $160.43
  • P/E Ratio
  • CTMX $5.36
  • VNRX N/A
  • Revenue Growth
  • CTMX 23.81
  • VNRX 64.16
  • 52 Week Low
  • CTMX $0.40
  • VNRX $0.40
  • 52 Week High
  • CTMX $3.10
  • VNRX $0.94
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 52.71
  • VNRX 47.94
  • Support Level
  • CTMX $2.33
  • VNRX $0.62
  • Resistance Level
  • CTMX $2.79
  • VNRX $0.76
  • Average True Range (ATR)
  • CTMX 0.18
  • VNRX 0.08
  • MACD
  • CTMX -0.01
  • VNRX -0.02
  • Stochastic Oscillator
  • CTMX 46.38
  • VNRX 12.47

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Share on Social Networks: